目的 分析2018—2019年徐州市腫瘤醫(yī)院門診患者麻醉藥品的使用現(xiàn)狀，為規(guī)范合理使用鎮(zhèn)痛藥物提供參考。方法 收集徐州市腫瘤醫(yī)院2018—2019年的門診麻醉處方共2 893張。對麻醉藥品的用藥品種、使用科室、使用患者年齡、用藥頻度（DDDs）、藥物利用指數(shù)（DUI）等進(jìn)行分析。結(jié)果 2018—2019年門診麻醉藥品共6個品種8個規(guī)格。阿桔片、鹽酸布桂嗪片、鹽酸羥考酮緩釋片（10 mg）的處方數(shù)比較多。使用麻醉藥品最多的科室為放療科、化療科和呼吸科，患者年齡主要為50～79歲。在癌痛治療第三階梯用藥中，鹽酸嗎啡緩釋片的DDDs最高，且DUI更接近于1。鹽酸羥考酮緩釋片（10 mg）的銷售金額最多。結(jié)論 徐州市腫瘤醫(yī)院門診麻醉藥品的使用基本合理，但醫(yī)生還需要對麻醉藥品的用藥頻次和用藥時間范圍進(jìn)一步的學(xué)習(xí)，藥師也要加強(qiáng)這方面的業(yè)務(wù)素質(zhì)并及時給予合理的干預(yù)，以促進(jìn)腫瘤患者的個體化用藥。

Objective To analyze the current situation of the use of narcotic drugs among outpatients in Xuzhou Cancer Hospital from 2018 to 2019, so as to provide references for standardizing the rational use of analgesics. Methods A total of 2 893 outpatient anesthetic prescriptions in Xuzhou Cancer Hospital from 2018 to 2019 were collected. The types of narcotic drugs, use departments, age of patients, frequency of drug use (DDDs), drug utilization index (DUI) and so on were analyzed. Results There were 6 varieties and 8 specifications of narcotic drugs in outpatient department from 2018 to 2019. Compound Platycodon, Bucinnazine Hydrochloride Tablets, and Oxycodone Hydrochloride Prolonged-release Tablets (10 mg) had the most number of prescriptions. The departments with the largest use of narcotic drugs were Department of Radiotherapy, Department of Chemotherapy, and Department of Respiratory. The age of patients was mainly 50 — 79 years old. In the treatment of cancer pain in the third step of medication, DDDs of Morphine Hydrochloride Slow-release Tablets was the highest, and DUI of it was close to 1. Consumption sum of Oxycodone Hydrochloride Prolonged-release Tablets (10 mg) was the most. Conclusion The use of narcotic drugs in outpatient pharmacy of Xuzhou Cancer Hospital from 2018 to 2019 is basically reasonable, but doctors need to further study the frequency and time range of narcotic drugs, and pharmacists should also strengthen their professional quality and give reasonable intervention in a timely manner, and in order to promote the individual use of drugs in tumor patients.

R971